Key Points
- Neurogene CFO Christine Mikail Cvijic sold 9,600 shares on May 6 at an average price of $31.25, totaling about $300,000. The trade was made under a pre-arranged Rule 10b5-1 plan.
- After the sale, Cvijic still owned 93,640 shares, and the transaction represented a 9.3% reduction in her position. She had also sold 4,045 shares in March.
- Neurogene recently reported a quarterly loss of $1.12 per share, beating analyst expectations, while Wall Street currently rates the stock Moderate Buy with a consensus price target of $67.00.
Neurogene Inc. (NASDAQ:NGNE - Get Free Report) CFO Christine Mikail Cvijic sold 9,600 shares of Neurogene stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $31.25, for a total value of $300,000.00. Following the transaction, the chief financial officer owned 93,640 shares of the company's stock, valued at $2,926,250. This trade represents a 9.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christine Mikail Cvijic also recently made the following trade(s):
- On Friday, March 13th, Christine Mikail Cvijic sold 4,045 shares of Neurogene stock. The shares were sold at an average price of $20.81, for a total value of $84,176.45.
Neurogene Stock Performance
NGNE stock opened at $30.77 on Friday. The company has a market capitalization of $480.63 million, a P/E ratio of -7.26 and a beta of 1.69. Neurogene Inc. has a 52-week low of $13.69 and a 52-week high of $37.27. The business has a 50-day simple moving average of $23.04 and a two-hundred day simple moving average of $22.07.
Neurogene (NASDAQ:NGNE - Get Free Report) last released its quarterly earnings results on Tuesday, March 24th. The company reported ($1.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.20) by $0.08. As a group, sell-side analysts forecast that Neurogene Inc. will post -5.35 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Neurogene
A number of hedge funds and other institutional investors have recently modified their holdings of NGNE. BNP Paribas Financial Markets boosted its stake in shares of Neurogene by 89.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company's stock worth $36,000 after buying an additional 978 shares during the last quarter. Daiwa Securities Group Inc. purchased a new position in Neurogene in the fourth quarter valued at approximately $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Neurogene by 17.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company's stock valued at $82,000 after purchasing an additional 1,059 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in Neurogene by 24.7% in the third quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company's stock valued at $88,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Neurogene in the fourth quarter valued at approximately $165,000. Hedge funds and other institutional investors own 52.37% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have recently weighed in on NGNE. Weiss Ratings restated a "sell (d-)" rating on shares of Neurogene in a research note on Tuesday, April 21st. HC Wainwright restated a "buy" rating and issued a $70.00 target price on shares of Neurogene in a research note on Tuesday, January 13th. Canaccord Genuity Group cut their target price on Neurogene to $180.00 and set a "buy" rating on the stock in a research note on Monday, April 6th. Lifesci Capital began coverage on Neurogene in a research note on Monday, January 26th. They issued an "outperform" rating and a $50.00 target price on the stock. Finally, Guggenheim began coverage on Neurogene in a research note on Tuesday, April 28th. They issued a "buy" rating and a $69.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Neurogene presently has an average rating of "Moderate Buy" and a consensus price target of $67.00.
Check Out Our Latest Research Report on NGNE
Neurogene Company Profile
(
Get Free Report)
Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company's lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene's pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.
Neurogene's proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
